Phase 2 multicenter maintenance study of golidocitinib, A JAK1 selective inhibitor, in patients with peripheral T cell lymphomas after first-line systemic therapy (JACKPOT26) - PubMed
3 hours ago
- #maintenance therapy
- #JAK1 inhibitor
- #PTCL
- Phase 2 study of golidocitinib (JAK1 inhibitor) as maintenance therapy for PTCL patients post first-line treatment.
- Two cohorts: Cohort 1 (CR, N=30) and Cohort 2 (PR, N=18) with transplant-ineligible patients.
- 24-month DFS rate in Cohort 1 was 74.2%; nodal subtypes showed 62.7% DFS.
- Cohort 2 had median PFS of 17.4 months; 24-month PFS rate was 48.6%.
- 50.0% of PR patients achieved CR with median response duration of 23.9 months.
- Common ≥grade 3 TRAEs were hematological (neutropenia, leukopenia) but manageable.
- 60.4% had TRAEs leading to treatment interruption; 10% discontinued.
- No fatal TRAEs reported; golidocitinib shows potential as PTCL maintenance therapy.